San Diego-based Genelux Corp. on Wednesday announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York treated the first patient in a Phase 1 clinical trial of GL-ONC1 in people with malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers.
The safety and dose-escalation study will, for the first time, evaluate GL-ONC1 administered through the lung cavity (intra-pleurally) as a single-agent therapy. Patients enrolled in the trial may have one of a number of possible cancer types, such as malignant pleural mesothelioma or non-small cell lung cancer (NSCLC).
Dr. Valerie W. Rusch, one of the world's leading thoracic surgeons and experts in mesothelioma, serves as principal investigator of the MSKCC-sponsored clinical trial.
Genelux is a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics.
The primary goal of the trial is to establish a recommended dose of GL-ONC1 when administered intrapleurally to patients with malignant pleural effusion, which is primarily attributable to NSCLC, malignant pleural mesothelioma (a cancerous tumor of the lining of the lung and chest cavity), and other cancers.